- Sanofi (SNY -0.3%) has sold the global rights to leukemia med Leukine (sargramostim) to privately held Partner Therapeutics for an undisclosed sum. The deal includes a dedicated manufacturing facility in Lynnwood, WA that was certified for commercial production in 2012.
- Partner plans to provide commercial and medical support in the U.S. while exploring commercial opportunities ex-U.S.
- Leukine is in various stages of development for a range of conditions, including muscular dystrophy, liver failure, autoimmune pulmonary alveolar proteinosis, breast cancer and melanoma.